Welcome to our dedicated page for LSBPW SEC filings (Ticker: LSBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LakeShore Biopharma Co., Ltd. files as a foreign private issuer, with Form 6-K reports documenting material events, governance matters, shareholder voting items, capital-structure disclosures, material agreements, and operating and financial results.
The company's filings also cover clinical or regulatory disclosures, security-structure matters, legal and arbitration developments involving affiliated biopharma entities, and its transition to the OTC market following a Nasdaq delisting.
LakeShore Biopharma’s controlling shareholder group filed Amendment No. 5 to its Schedule 13D, outlining a sharply revised going‑private proposal. The consortium now proposes to buy all publicly held ordinary shares at US$0.06 per share, compared with the prior US$0.90 offer, via equity funding and rollover of existing holdings.
The filing cites arbitral awards imposing approximately RMB576.5 million of monetary liabilities and related litigation uncertainty as key reasons for the lower price, warning these could materially weaken the company’s financial condition. If completed, the merger would take LakeShore private, terminate SEC registration and remove its shares from the OTC Pink market. The proposal remains non‑binding, with no assurance that definitive agreements or a transaction will be consummated.
LakeShore Biopharma’s controlling shareholder group filed Amendment No. 5 to its Schedule 13D, outlining a sharply revised going‑private proposal. The consortium now proposes to buy all publicly held ordinary shares at US$0.06 per share, compared with the prior US$0.90 offer, via equity funding and rollover of existing holdings.
The filing cites arbitral awards imposing approximately RMB576.5 million of monetary liabilities and related litigation uncertainty as key reasons for the lower price, warning these could materially weaken the company’s financial condition. If completed, the merger would take LakeShore private, terminate SEC registration and remove its shares from the OTC Pink market. The proposal remains non‑binding, with no assurance that definitive agreements or a transaction will be consummated.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.
LakeShore Biopharma Co., Ltd filed a Form 6-K as a foreign private issuer, mainly to furnish a press release about its stock trading status. The company announced a transition to trading on the OTC market following a Nasdaq delisting. The report is signed by Director and Chief Financial Officer Rachel Yu on September 22, 2025.
Amendment to Schedule 13D reporting that a consortium led by Oceanpine Investment, Oceanpine Capital and Crystal Investment has proposed a potential acquisition of all outstanding ordinary shares of LakeShore Biopharma Co., Ltd. The Revised Proposal values each ordinary share at US$0.86 in cash. Crystal Investment currently holds 21,021,332 shares (51.0%) based on 41,212,693 shares outstanding as of June 30, 2025. Oceanpine-held positions total 462,760 shares (1.1%), comprising 410,560 held by Oceanpine Investment and 52,200 by Oceanpine Capital.
The Consortium entered a Consortium Agreement providing for cooperative negotiation, exclusive collaboration among members for up to 24 months, and anticipated contributions of cash or shares to an acquisition vehicle. The Reporting Persons estimate approximately US$20,000,000 will be expended to acquire the publicly held shares at the Revised Proposal price. If consummated, the Proposed Transaction could result in delisting and termination of registration of the Ordinary Shares.